{
  "id": 8897206,
  "title": "Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts",
  "url": "https://urgent.news/2026/09/21/expect-high-tide-of-chinese-biotech-deals-as-threat-of-us-curbs-fades",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-21T10:00:10.000Z",
  "source": {
    "name": "South China Morning Post",
    "slug": "south-china-morning-post",
    "url": "https://www.scmp.com/business/china-business/article/3368249/expect-high-tide-chinese-biotech-deals-threat-us-curbs-fades-analysts"
  },
  "original_language": "en",
  "account": null,
  "summary": "US-China biotech deals are expected to thrive because Washington is reportedly leaning away from sweeping restrictions, according to analysts, giving Chinese healthcare firms a major boost following Beijing’s ambitious five-year plan for the sector. Out-licensing deals between China and the US would “ride on a high tide” in the favourable environment, said Nomura’s head of China healthcare…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "SCMP Business",
        "title": "Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts",
        "url": "https://urgent.news/2026/09/21/expect-high-tide-of-chinese-biotech-deals-as-threat-of-us-curbs-fades-8897225",
        "published": "2026-09-21T10:00:10.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}